Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4851867
Max Phase: Preclinical
Molecular Formula: C14H16ClN7
Molecular Weight: 317.78
Molecule Type: Unknown
Associated Items:
ID: ALA4851867
Max Phase: Preclinical
Molecular Formula: C14H16ClN7
Molecular Weight: 317.78
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1c(Cc2ccnn2C)c(-c2cc(Cl)nc(N)n2)nn1C
Standard InChI: InChI=1S/C14H16ClN7/c1-8-10(6-9-4-5-17-22(9)3)13(20-21(8)2)11-7-12(15)19-14(16)18-11/h4-5,7H,6H2,1-3H3,(H2,16,18,19)
Standard InChI Key: ZGUOXFQGWSWILI-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 317.78 | Molecular Weight (Monoisotopic): 317.1156 | AlogP: 1.75 | #Rotatable Bonds: 3 |
Polar Surface Area: 87.44 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 2.44 | CX LogP: 2.05 | CX LogD: 2.05 |
Aromatic Rings: 3 | Heavy Atoms: 22 | QED Weighted: 0.74 | Np Likeness Score: -1.62 |
1. Fushimi M, Buck H, Balbach M, Gorovyy A, Ferreira J, Rossetti T, Kaur N, Levin LR, Buck J, Quast J, van den Heuvel J, Steegborn C, Finkin-Groner E, Kargman S, Michino M, Foley MA, Miller M, Liverton NJ, Huggins DJ, Meinke PT.. (2021) Discovery of TDI-10229: A Potent and Orally Bioavailable Inhibitor of Soluble Adenylyl Cyclase (sAC, ADCY10)., 12 (8.0): [PMID:34413957] [10.1021/acsmedchemlett.1c00273] |
Source(1):